These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17923619)

  • 1. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Polman CH; Deisenhammer F; Giovannoni G; Killestein J; Schellekens H
    Neurology; 2007 Oct; 69(15):1553-4; author reply 1555. PubMed ID: 17923619
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Sorensen PS; Bertolotto A
    Neurology; 2007 Oct; 69(15):1552; author reply 1553. PubMed ID: 17923618
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Pachner AR
    Neurology; 2007 Oct; 69(15):1555; author reply 1565. PubMed ID: 17923620
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT
    Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC;
    Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
    Sorensen PS; Tscherning T; Mathiesen HK; Langkilde AR; Ross C; Ravnborg M; Bendtzen K
    Neurology; 2006 Nov; 67(9):1681-3. PubMed ID: 17101906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
    Hartung HP; Munschauer FE
    J Neurol; 2004 Jun; 251 Suppl 2():II40-2. PubMed ID: 15264111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Farrell R; Bendtzen K; Bertolotto A; Clark B; Comabella M; Deisenhammer F; Fogdell-Hahn A; Giovannoni G; Hartung HP; Hemmer B; Hillert J; Kappos L; Killestein J; Lindberg R; Montalban X; Polman C; Sorensen PS;
    J Int Med Res; 2008; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Manchikanti L; Boswell MV; Giordano J; Kaplan E
    Neurology; 2007 Sep; 69(11):1190; author reply 1190-1. PubMed ID: 17846419
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
    Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
    Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of neutralising antibodies on therapeutic efficacy.
    Bertolotto A
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S29-32. PubMed ID: 19200862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-based medicine and clinical trials.
    Coyle PK
    Neurology; 2007 Jun; 68(24 Suppl 4):S3-7. PubMed ID: 17562847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Stricker RB; Johnson L
    Neurology; 2008 May; 70(19):1719; author reply 1719-20. PubMed ID: 18458234
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
    Giovannoni G; Goodman A
    Neurology; 2005 Jul; 65(1):6-8. PubMed ID: 16009876
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
    Lapé Nixon M; Matud J; Yeh C; Prince HE
    J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 20. Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    ; Chaudhry V; Stevens JC; Kincaid J; So YT
    Neurology; 2006 Jun; 66(12):1805-8. PubMed ID: 16801641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.